Intraocular Lymphoma: Current Therapy and Future Trends

  • Christopher J. Calvano
  • Stella K. Kim
  • Dan S. Gombos
Part of the M.D. Anderson Solid Tumor Oncology Series book series (MDA, volume 6)


Intraocular lymphoma is a rare non-Hodgkin’s lymphoma with three main presentations: primary retinal lymphoma, primary uveal lymphoma, and secondary uveal lymphoma in a patient with known central nervous system lymphoma. Primary intraocular lymphomas are usually diffuse large B-cell lymphomas and generally are associated with a poor prognosis. Patients present with recurrent vitritis or uveitis that may initially respond to topical steroids. Some complain of increased floaters or generalized blurry vision. Cytologic evaluation is the mainstay of accurate diagnosis of primary intraocular lymphoma; genetic information from flow cytometry evaluation may also be useful. There is no clear consensus on treatment, but generally whole-eye radiotherapy should be considered, possibly after administration of systemic high-dose methotrexate.


Primary Central Nervous System Lymphoma Central Nervous System Involvement Central Nervous System Lymphoma World Health Organization Classification Scleral Flap 


  1. 1.
    Jaffe ES, et al. World Health Organization Classification of Tumors. Tumors of Hematopoietic and Lymphoid Tissues. Pathology and Genetics. Lyons: IARC Press, 2001.Google Scholar
  2. 2.
    Moslehi R, Devesa SS, Schairer C, et al. Rapidly increasing incidence of ocular non-Hodgkin lymphoma. J Natl Cancer Inst 2006;98:936–9.PubMedCrossRefGoogle Scholar
  3. 3.
    Gunduz K, Pulido JS, McCannel CA, et al. Ocular manifestations and treatment of central nervous system lymphoma. Neurosurg Focus 2006;21:E9.PubMedGoogle Scholar
  4. 4.
    Chan CC, Wallace DJ. Intraocular lymphoma: update on diagnosis and management. Cancer Control 2004;11:285–95.PubMedGoogle Scholar
  5. 5.
    Coupland SE, Heimann H, Bechrakis NE. Primary intraocular lymphoma: a review of the clinical histopathological and molecular biological features. Graefes Arch Clin Exp Ophthalmol 2004;242:901–13.PubMedCrossRefGoogle Scholar
  6. 6.
    Kim SK, Chan CC, Wallace DJ. Management of primary intraocular lymphoma. Curr Oncol Rep 2005;7:74–9.PubMedCrossRefGoogle Scholar
  7. 7.
    Chan CC, Buggage RR, Nussenblatt RB. Intraocular lymphoma. Curr Opin Ophthalmol 2002;13:411–8.PubMedCrossRefGoogle Scholar
  8. 8.
    Coupland SE, Damato B. Lymphoma involving the eye and ocular adnexa. Curr Opin Ophthalmol 2006;17:523–31.PubMedGoogle Scholar
  9. 9.
    Zaldivar RA, Martin DF, Holden JT, et al. Primary intraocular lymphoma: clinical, cytologic, and flow cytometric analysis. Ophthalmology 2004;111:1762–7.PubMedGoogle Scholar
  10. 10.
    Fortun JA, Carvounis PE, Albini TA, et al. Comparison of cytologic and flow cytometry features of vitreous samples obtained using 20- or 25-gauge vitrectomy for the diagnosis of lymphoma. Poster presented at Association for Research in Vision and Ophthalmology. 2007, Ft. Lauderdale, FL.Google Scholar
  11. 11.
    Karma A, von Willebrand EO, Tommila PV, et al. Primary intraocular lymphoma: improving the diagnostic procedure. Ophthalmology 2007;114:1372–7.PubMedCrossRefGoogle Scholar
  12. 12.
    Schulz H, Pels H, Schmidt-Wolf I, et al. Intraventricular treatment of relapsed central nervous system lymphoma with the anti-CD20 antibody rituximab. Haematologica 2004;89(6):753–4.PubMedGoogle Scholar
  13. 13.
    Rubenstein JL, Fridlyand J, Abrey L, et al. Phase I study of intraventricular administration of rituximab in patients with recurrent CNS and intraocular lymphoma. J Clin Oncol 2007;25(11):1350–6.PubMedCrossRefGoogle Scholar
  14. 14.
    Maloney DG, Smith B, Rose A. Rituximab: mechanism of action and resistance. Semin Oncol 2002;29(1 Suppl 2):2–9.PubMedCrossRefGoogle Scholar
  15. 15.
    Kitzmann AS, Pulido JS, Mohney BG, et al. Intraocular use of rituximab. Eye 2007;21(12):1524–7.PubMedCrossRefGoogle Scholar
  16. 16.
    Kim H, Csaky KG, Chan CC, et al. The pharmacokinetics of rituximab following an intravitreal injection. Exp Eye Res 2006;82(5):760–6.PubMedCrossRefGoogle Scholar
  17. 17.
    Mineo JF, Scheffer A, Karkoutly C, et al. Using human CD20-transfected murine lymphomatous B cells to evaluate the efficacy of intravitreal and intracerebral rituximab injections in mice. Invest Ophthalmol Vis Sci 2008;49(11):4738–45.PubMedCrossRefGoogle Scholar
  18. 18.
    Ohguro N, Hashida N, Tano Y. Effect of intravitreous rituximab injections in patients with recurrent ocular lesions associated with central nervous system lymphoma. Arch Ophthalmol 2008;126(7):1002–3.PubMedCrossRefGoogle Scholar
  19. 19.
    Bakri SJ, Cameron JD, McCannel CA, et al. Absence of histologic retinal toxicity of intravitreal bevacizumab in a rabbit model. Am J Ophthalmol 2006;142(1):162–4.PubMedCrossRefGoogle Scholar
  20. 20.
    Itty S, Pulido JS. Rituximab for intraocular lymphoma. Retina 2009;29(2):129–32.PubMedCrossRefGoogle Scholar
  21. 21.
    Nussenblatt RB, Chan CC, Wilson WH, et al. International Central Nervous System and Ocular Lymphoma Workshop: recommendations for the future. Ocul Immunol Inflamm 2006;14(3):139–44.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • Christopher J. Calvano
    • 1
  • Stella K. Kim
    • 2
  • Dan S. Gombos
    • 2
  1. 1.Division of Ophthalmic Plastic SurgeryKresge Eye Institute, Wayne State UniversityDetroitUSA
  2. 2.Section of Ophthalmology, Department of Head and Neck SurgeryThe University of Texas M.D. Anderson Cancer CenterHoustonUSA

Personalised recommendations